|Bid||28.97 x 1000|
|Ask||31.24 x 1100|
|Day's range||28.55 - 29.09|
|52-week range||16.75 - 37.11|
|Beta (5Y monthly)||0.99|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||37.00|
Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.86% and 29.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.